NCT04230785 Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)
| NCT ID | NCT04230785 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nanjing First Hospital, Nanjing Medical University |
| Condition | Stroke, Acute |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2020-03-15 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2020-03-15 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
EVTRNA is to analyze the differentiated expression pattern of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA) by next-generation sequencing in acute ischemic stroke patients before and/or after endovascular treatment. The candidate circRNA/lncRNA/miRNA will be verified as the biomarker and regulator for progression and prognosis of acute ischemic stroke with endovascular treatment. Further, the candidate non-coding RNA will be used to evaluate the effect of endovascular treatment on both peripheral and central immune after stroke.
Eligibility Criteria
Inclusion Criteria: * Aged 18 years or older * Confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on magnetic resonance imaging (MRI) and a new lesion on a brain computed tomography (CT) scan * Within 24 hours of symptom onset and treat with endovascular therapy * Good performance status * Signed an approved informed consents Exclusion Criteria: * a history of hemorrhagic infarction, chronic kidney/liver diseases, peripheral arterial occlusive disease, active malignant disease, and inflammatory or infectious diseases
Contact & Investigator
Junshan Zhou, M.D
STUDY CHAIR
Nanjing First Hospital, Nanjing Medical University
Frequently Asked Questions
Who can join the NCT04230785 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Stroke, Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04230785 currently recruiting?
Yes, NCT04230785 is actively recruiting participants. Contact the research team at zhjsh333@126.com for enrollment information.
Where is the NCT04230785 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT04230785 clinical trial?
NCT04230785 is sponsored by Nanjing First Hospital, Nanjing Medical University. The principal investigator is Junshan Zhou, M.D at Nanjing First Hospital, Nanjing Medical University. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.